1. Home
  2. Stocks
  3. Biocon Share Price
  • Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • Similar Stocks
  • FAQs

    • Biocon Share Price

    Large Cap
    ₹352.2
    + 5.7 (1.65%)
    • Advice
    • Hold
    15 October, 2024 19:23 BSE: 532523 NSE: BIOCON ISIN: INE376G01013

    Start SIP in Biocon

    Start SIP

    Biocon Performance

    Day Range

    • Low 346
    • High 353
    ₹ 352

    52 Week Range

    • Low 218
    • High 396
    ₹ 352
    • Open Price347
    • Previous Close347
    • Volume2051189

    Biocon Chart

    • Over 1 Month -7.06%
    • Over 3 Month + 0.41%
    • Over 6 Month + 28.54%
    • Over 1 Year + 38.36%

    Biocon Key Statistics

    P/E Ratio 26.7
    PEG Ratio 0.1
    Market Cap Cr 42,285
    Price to Book Ratio 1.7
    EPS 0.9
    Dividend 0.1
    Relative Strength Index 45.88
    Money Flow Index 27.73
    MACD Signal -3.41
    Average True Range 10.67

    Biocon F&O

    Biocon Futures Biocon Option Chain

    Biocon Investment Rating

    • Master Rating:

    • Biocon (Nse) has an operating revenue of Rs. 14,766.00 Cr. on a trailing 12-month basis. An annual revenue growth of 35% is outstanding, Pre-tax margin of 11% is healthy, ROE of 5% is fair but needs improvement. The company has a debt to equity of 65%, which is bit higher. The stock from a technical standpoint is trading below to its 50DMA and around 10% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -8% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 58 which is a POOR score indicating inconsistency in earnings, a RS Rating of 53 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 92 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Biocon Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 511533563519513507
    Operating Expenses Qtr Cr 466480492452441551
    Operating Profit Qtr Cr 4552716772-44
    Depreciation Qtr Cr 313031313029
    Interest Qtr Cr 554056554848
    Tax Qtr Cr 089113-15
    Net Profit Qtr Cr 1142435471,811
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 2,3202,264
    Operating Expenses Annual Cr 1,8651,969
    Operating Profit Annual in Cr 26324
    Depreciation Cr 121117
    Interest Annual Cr 19970
    Tax Annual Cr 31123
    Net Profit Annual Cr 1192,848
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr -123219
    Cash from Investing Activity Annual Cr -296-1,178
    Cash from Financing Annual Activity Cr 3441,039
    Net Cash Flow Annual Cr -7681
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 10,91210,916
    Fixed Assets Annual Cr 1,5181,305
    Total Non Current Assets Annual Cr 11,00810,464
    Total Current Assets Annual Cr 2,7602,566
    Total Assets Annual Cr 13,76813,030
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 9191
    ROE Annual % 126
    ROCE Annual % 31
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2115
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 3,4333,8643,5493,4623,4233,774
    Operating Expenses Qtr Cr 2,8133,0013,0272,7212,7082,777
    Operating Profit Qtr Cr 620916927742714997
    Depreciation Qtr Cr 405407415389358364
    Interest Qtr Cr 236227267248233249
    Tax Qtr Cr 2849655423582
    Net Profit Qtr Cr 660136660126101313
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 15,62111,550
    Operating Expenses Annual Cr 11,4578,663
    Operating Profit Annual in Cr 3,2992,512
    Depreciation Cr 1,5691,113
    Interest Annual Cr 974419
    Tax Annual Cr 227254
    Net Profit Annual Cr 1,023463
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 2,9541,853
    Cash from Investing Activity Annual Cr -1,005-14,282
    Cash from Financing Annual Activity Cr -2,33313,049
    Net Cash Flow Annual Cr -383619
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 19,78417,867
    Fixed Assets Annual Cr 22,26520,649
    Total Non Current Assets Annual Cr 40,89239,709
    Total Current Assets Annual Cr 15,17912,334
    Total Assets Annual Cr 56,07152,043
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 211187
    ROE Annual % 53
    ROCE Annual % 64
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2826
    Invest in Biocon

    Biocon Technicals

    EMA & SMA

    Current Price
    ₹352.2
    + 5.7 (1.65%)
    pointer
    • Bullish Moving Average
    • ___
    • 9
    • Bearish Moving Average
    • ___
    • 7
    • 20 Day
    • ₹356.17
    • 50 Day
    • ₹356.80
    • 100 Day
    • ₹345.10
    • 200 Day
    • ₹322.31
    • 20 Day
    • ₹359.14
    • 50 Day
    • ₹358.27
    • 100 Day
    • ₹350.12
    • 200 Day
    • ₹313.81

    Biocon Resistance and Support

    PIVOT
    ₹350.64
    Resistance
    First Resistance 354.92
    Second Resistance 357.63
    Third Resistance 361.92
    RSI 45.88
    MFI 27.73
    MACD Single Line -3.41
    MACD -5.18
    Support
    First Support 347.92
    Second Support 343.63
    Third Supoort 340.92

    Biocon Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 1,285,587 54,097,501 42.08
    Week 1,822,720 72,161,469 39.59
    1 Month 4,492,896 167,719,798 37.33
    6 Month 7,261,542 272,598,302 37.54

    Biocon Result Highlights

    Biocon Synopsis

    NSE-Medical-Biomed/Biotech

    Biocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 2127.30 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2024. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.
    Market Cap 41,601
    Sales 2,125
    Shares in Float 46.82
    No of funds 273
    Yield 0.14
    Book Value 3.81
    U/D Vol ratio 1.1
    LTDebt / Equity 19
    Alpha -0.02
    Beta 1.3

    Biocon Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23
    Promoters 60.64%60.64%60.64%
    Mutual Funds 8.69%8.57%9.31%
    Insurance Companies 5.51%5.01%5.12%
    Foreign Portfolio Investors 5.9%5.63%6.55%
    Financial Institutions/ Banks 0.02%0.01%
    Individual Investors 14.64%15.53%14.47%
    Others 4.6%4.61%3.91%

    Biocon Management

    Name Designation
    Ms. Kiran Mazumdar Shaw Executive Chairperson
    Mr. Siddharth Mittal Managing Director & CEO
    Prof. Ravi Rasendra Mazumdar Non Exe.Non Ind.Director
    Mr. Eric Vivek Mazumdar Non Exe.Non Ind.Director
    Mr. Meleveetil Damodaran Independent Director
    Mr. Bobby Kanubhai Parikh Independent Director
    Mr. Naina Lal Kidwai Independent Director
    Ms. Rekha Mehrotra Menon Independent Director
    Mr. Nicholas Robert Haggar Independent Director
    Mr. Atul Dhawan Independent Director

    Biocon Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Biocon Corporate Action

    Date Purpose Remarks
    2024-10-30 Quarterly Results
    2024-08-08 Quarterly Results
    2024-05-16 Audited Results & Final Dividend
    2024-02-08 Quarterly Results
    2023-11-10 Quarterly Results
    Date Purpose Remarks
    2024-07-05 FINAL Rs.0.50 per share(10%)Final Dividend
    2023-07-07 FINAL Rs.1.50 per share(30%)Final Dividend
    2022-07-01 FINAL Rs.0.50 per share(10%)Final Dividend

    About Biocon

    Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bengaluru, India. The company has more than 16,545 employees as on March 2023. It focuses on all phases of the product cycle from researching to development and then introducing them to the market. They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies. 

    Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine) & so on. 

    Biocon FAQs

    What is Share Price of Biocon ?

    Biocon share price is ₹352 As on 15 October, 2024 | 19:09

    What is the Market Cap of Biocon ?

    The Market Cap of Biocon is ₹42285.1 Cr As on 15 October, 2024 | 19:09

    What is the P/E ratio of Biocon ?

    The P/E ratio of Biocon is 26.7 As on 15 October, 2024 | 19:09

    What is the PB ratio of Biocon ?

    The PB ratio of Biocon is 1.7 As on 15 October, 2024 | 19:09

    Is it a good time to invest in Biocon Limited?

    Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.

    How many times has Biocon Limited given dividends since 2004?

    Biocon Ltd. has declared 17 dividends since July 1, 2004.

    What is the stock price CAGR of Biocon Limited?

    The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.

    What is the debt-to-equity ratio of Biocon Limited?

    The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.

    What is the ROE of the Biocon Limited?

    The ROE of Biocon Limited is 9% which is fair but needs improvement.

    Who is the Managing Director of Biocon Limited?

    Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.

    Is Biocon a good stock to buy?

    According to the record analysis of moneyworks4me, Biocom limited is an average quality company. 

    How to buy shares of Biocon Ltd?

    The company's shares can be bought online by opening a demat account with 5paisa in either web or app.

    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

    Q2FY23

    5paisa Capital Ltd. CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.